T. Seay

发表

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

N. Petrelli, N. Wolmark, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

N. Petrelli, N. Wolmark, M. O’connell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

N. Wolmark, M. O’connell, C. Allegra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

J. Kopec, D. Cella, J. Costantino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin

N. Wolmark, M. O’connell, Roy E. Smith, 2007, Cancer.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

N. Petrelli, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.

T. Julian, J. Costantino, N. Wolmark, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

W. McCaskill-Stevens, T. Julian, J. Costantino, 2013, Breast Cancer Research and Treatment.

Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

M. Hidalgo, M. Reni, J. Tabernero, 2013 .

Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

M. Hidalgo, M. Reni, E. Van Cutsem, 2013 .

Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07).

J. Wheeler, J. Atkins, C. Scott, 2001, International journal of radiation oncology, biology, physics.

A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42

S. Paik, C. Geyer, S. Swain, 2019 .

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.

J. Abbruzzese, M. Rothenberg, T. Seay, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

N. Wolmark, M. O’connell, C. Allegra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial

S. Alberts, G. Farr, J. Reid, 2012, American journal of clinical oncology.

Generation, Isolation and Assay Methods for Human Lymphocyte Mitogenic Factor

T. Seay, 1982 .

Amphotericin B modifications of peripheral blood lymphocyte and tonsil lymphocyte responses to concanavalin A.

T. Seay, F. Inman, 1982, International journal of immunopharmacology.

Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.

S. Lippman, P. Philip, C. Moinpour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Greg Yothers, Michael Ewer, Norman Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

S. Paik, C. Geyer, D. Wickerham, 2019, The Lancet. Oncology.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.